Recently, US FDA Inspected BECRO for one more time, and the Outcome of the Inspection was again Positive with No Observations. The aim of the FDA Inspection was to determine whether the activities and procedures of BECRO complied with 21 CFR Part 320 – Bioavailability and Bioequivalence (BE). In particular, FDA conducted this inspection to
BECRO is participating as Exhibitor at CPhI Milan 2024 (8-10 October), Stand 24D44. BECRO is specialized in the conduct of BECRO offers clinical trials services all the way from study set up to submission. In addition, BECRO specializes in drafting modules of CDT and CERs for Medical Devices, and in preparing CDT and CDISC for
CPhI Barcelona 2023 BECRO is participating as Exhibitor at CPhI Barcelona 2023 (24-26 October), Stand 80E40, zone API. BECRO offers clinical trials services all the way from study set up to submission. In addition, BECRO specializes in drafting modules of CDT and CERs for Medical Devices, and in preparing CDT and CDISC for US FDA submissions. BECRO was
BECRO is participating as Exhibitor at CPhI Worldwide Frankfurt 2022 (1-3 November), Stand 91A68, Hall 9.1. BECRO offers clinical trials services all the way from study set up to submission. In addition, BECRO specializes in drafting modules of CDT and CERs for Medical Devices, and in preparing CDT and CDISC for US FDA submissions. BECRO
BECRO Ltd was inspected by US FDA, recently, and the outcome of the inspection was positive
EMA/CHMP arbitration procedures
M.Sc. “Research Methodology in Biomedicine, Biostatistics and Clinical Bioinformatics” at University of Thessaly